Released May 8, 2025, after the close
10-Q filed May 8, 2025, 38 days after period end · 0000950170-25-066991
Q1 2025 · 10-Q
Revenue$9.42M$9.42M +62.8% vs Q1 2024+28.0% vs Q4 2024
Net Income-$8.82M-$8.82M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$1.17-$1.17 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$9,941,000N/M
Operating Cash Flow-$23,439,000N/M
Free Cash Flowderived-$23,439,000N/M
Margins · derived
Operating margin-105.5%+79.9 pt vs Q1 2024
Net margin-93.6%+63.3 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $9.42M | $5.79M | $0.00 | — |
| Net Income | -$8.82M | -$9.08M | -$18.95M | -$23.09M |
| EPS Diluted | -$1.17 | -$1.66 | -$4.46 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR